# Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan)

> **NCT00716625** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 1674 (actual)

## Conditions studied

- Carcinoma, Renal Cell

## Interventions

- **DRUG:** sunitinib malate

## Key facts

- **NCT ID:** NCT00716625
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 1674 (ACTUAL)
- **Last updated:** 2023-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00716625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00716625, "Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00716625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*